NASDAQ · Drug Manufacturers - Specialty & Generic

Gelteq Limited (GELS) Stock

$0.56 +1.28% NASDAQ: GELS Healthcare

Valuation

MetricValue
Price$0.56
Market Cap$5.10M
P/E Ratio-2.08
P/B Ratio0.55
P/S Ratio38.49
EPS (TTM)$0.00
52-Week High$2.01
52-Week Low$0.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-24.94%
ROA-18.59%
ROCE-24.88%
Gross Margin100.00%
Operating Margin-33.18%
Net Margin-40.12%
Debt/Equity0.36
Current Ratio0.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-3.0M$-3.0M$-3.0M$-5.0M
Net Profit$-1.0M$-3.0M$-4.0M$-4.0M$-7.0M
EPS$-0.07$-0.36$-0.37$0.00$0.00
Op Margin—-2164.4%-3885.3%—-3317.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$24.0M$23.0M$22.0M$21.0M$21.0M
Total Liabilities$0$3.0M$4.0M$6.0M$6.0M
Cash$0$0$0$0$0
Borrowings$0$2.0M$2.0M$4.0M$4.0M

Latest News

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs GlobeNewswire · Jun 17, 2026 Top Premarket Gainers MT Newswires · Jun 15, 2026 Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications GlobeNewswire · Jun 12, 2026 Top Premarket Decliners MT Newswires · Jun 12, 2026 Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$0$-2.0M$-1.0M$-6.0M
Investing Cash Flow$0$0$0$0$-1.0M
Financing Cash Flow$0$0$0$0$-2.0M
Net Cash Flow$0$0$0$0$0
Free Cash Flow$0$-2.0M$-2.0M$-1.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-4.10
FCF Yield0.00%
Quick Ratio0.09
Interest Coverage-3.93
Return 1Y-69.36%
Return 3Y—
Return 5Y—

Ownership

Insiders Held47.53%
Institutions Held0.58%
Institutions Float Held1.11%
Institutional HolderSharesReport Date
Wedbush Securities Inc20,0002026-03-31
Private Advisor Group, LLC16,6682026-03-31
Citadel Advisors Llc13,8302026-03-31
Two Sigma Investments, LP10,0522026-03-31
UBS Group AG1,8342026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AYTUAytu BioPharma, Inc. $2.03 -1.22% -1.51 $21.73M 0.00%
BFRGBullfrog AI Holdings, Inc. $0.65 -6.70% -1.26 $11.98M 0.00%
BFRIBiofrontera Inc. $0.97 +5.72% -1.69 $12.44M 0.00%
BGLCBioNexus Gene Lab Corp $1.29 +3.20% -1.01 $3.12M 0.00%
COCPCocrystal Pharma, Inc. $1.07 +0.00% -1.49 $14.75M 0.00%

About Gelteq Limited

Gelteq Limited is led by CEO Nathan Jacob Givoni, publicly traded since 2024.

Gelteq Limited (GELS) stock trades at $0.56 with a market capitalization of $5.10M. The stock is valued at a price-to-earnings (P/E) ratio of -2.08, price-to-book of 0.55, price-to-sales of 38.49. Over the past 52 weeks the stock has ranged between $0.39 and $2.01, and currently trades 72.1% below its 52-week high.

On profitability, Gelteq Limited generates a return on equity (ROE) of -24.94%, return on capital employed of -24.88%, an operating margin of -33.18%, a net profit margin of -40.12%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides